Publikationen in Zusammenarbeit mit Forschern von Hospital Universitari Germans Trias i Pujol (15)

2022

  1. Discovering HIV related information by means of association rules and machine learning

    Scientific Reports, Vol. 12, Núm. 1

2019

  1. Comparison of safety and vector-specific immune responses in healthy and HIV-infected populations vaccinated with MVA-B

    Vaccines, Vol. 7, Núm. 4

  2. Virological outcome measures during analytical treatment interruptions in chronic HIV-1-infected patients

    Open Forum Infectious Diseases, Vol. 6, Núm. 12

2017

  1. Simplification to dual therapy (atazanavir/ritonavir1lamivudine) versus standard triple therapy [atazanavir/ritonavir1two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study)

    Journal of Antimicrobial Chemotherapy, Vol. 72, Núm. 1, pp. 246-253

2016

  1. Costs and cost-effectiveness analysis of 2015 GESIDA/Spanish AIDS National Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 34, Núm. 6, pp. 361-371

2015

  1. A phase i randomized therapeutic MVA-B vaccination improves the magnitude and quality of the T cell immune responses in HIV-1-infected subjects on HAART

    PLoS ONE, Vol. 10, Núm. 11

  2. Comparison of the prognostic value of liver biopsy and FIB-4 index in patients coinfected with HIV and hepatitis C virus

    Clinical Infectious Diseases, Vol. 60, Núm. 6, pp. 950-958

  3. Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study

    PLoS Medicine, Vol. 12, Núm. 3

  4. Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial

    The Lancet Infectious Diseases, Vol. 15, Núm. 7, pp. 775-784

2014

  1. Documento de consenso de GeSIDA/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana (Actualización enero 2014)

    Enfermedades Infecciosas y Microbiologia Clinica Monografias, Vol. 32, Núm. 7, pp. 446e1-446e42

  2. Effects of sustained viral response in patients with HIV and chronic hepatitis C and nonadvanced liver fibrosis

    Journal of Acquired Immune Deficiency Syndromes, Vol. 66, Núm. 3, pp. 280-287

  3. Executive summary of the GeSIDA/National AIDS Plan consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2014)

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 32, Núm. 7, pp. 447-458

  4. Opportunistic infections and AIDS malignancies early after initiating combination antiretroviral therapy in high-income countries

    AIDS, Vol. 28, Núm. 16, pp. 2461-2473

2013

  1. Risk, predictors, and mortality associated with non-AIDS events in newly diagnosed HIV-infected patients: Role of antiretroviral therapy

    AIDS, Vol. 27, Núm. 2, pp. 181-189

2008

  1. Low rate of adverse hepatic events associated with fosamprenavir/ritonavir-based antiretroviral regimens

    HIV Clinical Trials, Vol. 9, Núm. 5, pp. 309-313